

Prescribing information

1. NAME OF THE MEDICINAL PRODUCT

AFINITOR[®] (everolimus)

Afinitor[®] 2.5 mg

Afinitor[®] 5 mg

Afinitor[®] 10 mg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Afinitor[®] 2.5 mg tablet contains 2.5 mg everolimus.

Afinitor[®] 5 mg tablet contains 5 mg everolimus

Afinitor[®] 10 mg tablet contains 10 mg everolimus

Excipient with known effect:

Each Afinitor[®] 2.5 mg tablet contains 74 mg lactose.

Each Afinitor[®] 5 mg tablet contains 149 mg lactose.

Each Afinitor[®] 10 mg tablet contains 297 mg lactose.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score.

- **2.5 mg:** The tablets are engraved with "LCL" on one side and "NVR" on the other.
- **5 mg:** The tablets are engraved with "5" on one side and "NVR" on the other.
- **10 mg:** The tablets are engraved with "UHE" on one side and "NVR" on the other.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Afinitor 2.5, 5 & 10mg are indicated for the:

1. Treatment of patients with SEGA associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of AFINITOR is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.
2. Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of AFINITOR[®] in the treatment of patients with carcinoid tumors have not been established.
3. Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
4. Treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes.
5. Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.
6. Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease (see sections 4.4 and 5.1).

4.2 Posology and method of administration

Treatment with Afinitor should be initiated and supervised by a physician experienced in the use of anticancer therapies or in the treatment of patients with TSC and therapeutic drug monitoring.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

Posology

For the different dose regimens Afinitor is available as 2.5 mg, 5 mg and 10 mg tablets. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

Oncology patients

The recommended dose is 10 mg everolimus once daily.

Renal angiomyolipoma associated with TSC

The recommended dose is 10 mg of everolimus once daily.

SEGA associated with TSC

Careful titration may be required to obtain the optimal therapeutic effect. Doses that will be tolerated and effective vary between patients. Concomitant antiepileptic therapy may affect the metabolism of everolimus and may contribute to this variance (see section 4.5).

Dosing is individualized based on Body Surface Area (BSA, in m²) using the Dubois formula, where weight (W) is in kilograms and height (H) is in centimeters:

$$BSA = (W^{0.425} \times H^{0.725}) \times 0.007184$$

The recommended starting daily dose for Afinitor for the treatment of patients with TSC who have SEGA is 4.5 mg/m². Different strengths of Afinitor tablets can be combined to attain the desired dose. Everolimus whole blood trough concentrations should be assessed at least 1 week after commencing treatment for patients <3 years of age and approximately 2 weeks after commencing treatment for patients ≥3 years of age. Dosing should be titrated to attain trough concentrations of 5 to 15 ng/ml. The dose may be increased to attain a higher trough concentration within the target range to obtain optimal efficacy, subject to tolerability.

Dosing recommendations for paediatric patients with SEGA are consistent with those for the adult SEGA population, except for patients with hepatic impairment (see “Hepatic impairment” below and section 5.2).

SEGA volume should be evaluated approximately 3 months after commencing Afinitor therapy, with subsequent dose adjustments taking changes in SEGA volume, corresponding trough concentration, and tolerability into consideration.

Once a stable dose is attained, trough concentrations should be monitored every 3 to 6 months in patients with changing body surface area or every 6 to 12 months in patients with stable body surface area for the duration of treatment.

For all indications:

If a dose is missed, the patient should not take an additional dose, but take the usual prescribed next dose.

Dose adjustments due to adverse drug reactions

Management of severe and/or intolerable suspected adverse drug reactions (ADRs) may require dose reduction and/or temporary interruption of Afinitor therapy. For adverse reaction of Grade 1, dose adjustment is usually not required. If dose reduction is required for oncology patients, the recommended dose is 5 mg daily and must not be lower than 5 mg daily.

If dose reduction is required for -TSC patients the recommended dose is approximately 50%

lower than the daily dose previously administered .For dose reductions below the lowest available strength, alternate day dosing should be considered.

Table 1 summarises dose adjustment recommendations for specific adverse reactions (see also section 4.4).

Table 1 Afinitor dose adjustment recommendations

Adverse Drug Reaction	Severity¹	Afinitor Dose Adjustment
Non-infectious pneumonitis	Grade 2	Consider interruption of therapy, until symptoms improve to Grade ≤ 1. Re-initiate Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
	Grade 3	Discontinue treatment if failure to recover within 4 weeks. Interrupt Afinitor until symptoms resolve to Grade ≤1. Consider re-initiating Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients). If toxicity recurs at Grade 3, consider discontinuation.
	Grade 4	Discontinue Afinitor treatment. .
Stomatitis	Grade 2	Temporary dose interruption until recovery to Grade ≤1. Re-initiate Afinitor at same dose. If stomatitis recurs at Grade 2, interrupt dose until recovery to Grade ≤1. Re-initiate Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).

Adverse Drug Reaction	Severity¹	Afinitor Dose Adjustment
	Grade 3	Temporary dose interruption until recovery to Grade ≤1. Re-initiate Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
	Grade 4	Discontinue Afinitor treatment.
Other non-hematologic toxicities (excluding metabolic events)	Grade 2	If toxicity is tolerable, no dose adjustment required. If toxicity becomes intolerable, temporary dose interruption until recovery to Grade ≤1. Re-initiate Afinitor at same dose. If toxicity recurs at Grade 2, interrupt Afinitor until recovery to Grade ≤1. Re-initiate Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
	Grade 3	Temporary dose interruption until recovery to Grade ≤1. Consider re-initiating Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients). If toxicity recurs at Grade 3, consider discontinuation.
	Grade 4	Discontinue Afinitor treatment.
Metabolic events (e.g. hyperglycemia, dyslipidemia)	Grade 2	No dose adjustment required.

Adverse Drug Reaction	Severity¹	Afinitor Dose Adjustment
	Grade 3	Temporary dose interruption. Re-initiate Afinitor (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
	Grade 4	Discontinue Afinitor treatment.
Thrombocytopenia	Grade 2 (<75 , $\geq 50 \times 10^9/l$)	Temporary dose interruption until recovery to Grade ≤ 1 ($\geq 75 \times 10^9/l$). Re-initiate treatment at same dose
	Grade 3 & 4 ($< 50 \times 10^9/l$)	Temporary dose interruption until recovery to Grade ≤ 1 ($\geq 75 \times 10^9/l$). Re-initiate treatment (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
Neutropenia	Grade 2 ($\geq 1 \times 10^9/l$)	No dose adjustment required.
	Grade 3 (< 1 , $\geq 0.5 \times 10^9/l$)	Temporary dose interruption until recovery to Grade ≤ 2 ($\geq 1 \times 10^9/l$). Re-initiate treatment at same dose.
	Grade 4 ($< 0.5 \times 10^9/l$)	Temporary dose interruption until recovery to Grade ≤ 2 ($\geq 1 \times 10^9/l$). Re-initiate treatment (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients)..
Febrile neutropenia	Grade 3	Temporary dose interruption until recovery to Grade ≤ 2 ($\geq 1.25 \times 10^9/l$) and no fever. Re-initiate treatment (5 mg daily for oncology patients and approximately 50% lower than the daily dose previously administered for TSC patients).
	Grade 4	Discontinue Afinitor treatment.

¹ Grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0

Therapeutic drug monitoring for patients treated for TSC

Therapeutic drug monitoring of everolimus blood concentrations, using a validated assay, is **required** for patients treated for SEGA. Trough concentrations should be assessed approximately 2 weeks after the initial dose, after any change in dose or pharmaceutical form, after initiation of or change in co-administration of CYP3A4 inducers or inhibitors (see sections 4.4 and 4.5) or after any change in hepatic status (Child-Pugh) (see “Hepatic impairment” below and section 5.2). For patients <3 years of age, trough concentrations should be monitored at least 1 week after start of treatment or after any change in dose or pharmaceutical form (see section 5.2).

Therapeutic drug monitoring of everolimus blood concentrations, using a validated assay, is an **option** to be considered for patients treated for renal angiomyolipoma associated with TSC (see section 5.1) after initiation of or change in co-administration of CYP3A4 inducers or inhibitors (see sections 4.4 and 4.5) or after any change in hepatic status (Child-Pugh) (see “Hepatic impairment” below and section 5.2).

When possible, the same assay and laboratory for therapeutic drug monitoring should be used throughout the treatment.

Special populations – For all indications

Elderly patients (≥65 years)

No dose adjustment is required (see section 5.2).

Renal impairment

No dose adjustment is required (see section 5.2).

Hepatic impairment

For Oncology patients and patients treated for TSC with renal angiomyolipoma:

- Mild hepatic impairment (Child-Pugh A) – the recommended dose is 7.5 mg daily.
 - Moderate hepatic impairment (Child-Pugh B) – the recommended dose is 5 mg daily.
 - Severe hepatic impairment (Child-Pugh C) – Afinitor is only recommended if the desired benefit outweighs the risk. In this case, a dose of 2.5 mg daily must not be exceeded.
- Dose adjustments should be made if a patient’s hepatic (Child-Pugh) status changes during treatment (see also sections 4.4 and 5.2).

Patients with SEGA associated with TSC:

Patients <18 years of age:

Afinitor a is not recommended for patients <18 years of age with SEGA and hepatic impairment

Patients ≥18 years of age:

- Mild hepatic impairment (Child-Pugh A): 75% of the recommended starting dose calculated based on BSA (rounded to the nearest strength)
- Moderate hepatic impairment (Child-Pugh B): 25% of the recommended starting dose calculated based on BSA (rounded to the nearest strength)
- Severe hepatic impairment (Child-Pugh C): not recommended

Everolimus whole blood trough concentrations should be assessed approximately 2 weeks after any change in hepatic status (Child-Pugh).

Paediatric population

The safety and efficacy of Afinitor in pediatric (children aged 0 to 18 years) oncology patients; have not been established. No data are available.

The safety and efficacy of Afinitor in children aged 0 to 18 years with renal angiomyolipoma associated with TSC in the absence of SEGA have not been established. No data are available.

The safety, efficacy and pharmacokinetic profile of Afinitor in children below the age of 1 year with TSC who have SEGA have not been established. No data are available (see sections 5.1 and 5.2).

Clinical study results did not show an impact of Afinitor on growth and pubertal development.

Method of Administration

Afinitor must be administered orally once daily at the same time every day, consistently either with or without food (see section 5.2).Afinitor tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.

For patients with TSC who have SEGA and are unable to swallow tablets, Afinitor Tablet(s) can be dispersed completely in a glass with approximately 30 mL of water by gently stirring until the tablet(s) is fully disintegrated (approximately 7 minutes) , immediately prior to drinking. After the dispersion has been swallowed, any residue must be re-dispersed in the same volume of water and swallowed (see section 5.2).

4.3 Contraindications

Hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients listed in section 6.1

4.4 Special warnings and precautions for use

Non-infectious pneumonitis

Non-infectious pneumonitis is a class effect of rapamycin derivatives, including everolimus. Non-infectious pneumonitis (including interstitial lung disease) has been frequently reported in patients taking Afinitor (see section 4.8) and was described very commonly in patients taking Afinitor for the advanced renal cell carcinoma (RCC) setting. Some cases were severe and on rare occasions, a fatal outcome was observed.

A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, pleural effusion, cough or dyspnea, and in whom infectious, neoplastic, and other non-medicinal causes have been excluded by means of appropriate investigations. Opportunistic infections such as pneumocystis jirovecii (carinii), pneumonia (PJP, PCP) should be ruled out in the differential diagnosis of non-infectious pneumonitis (see “Infections” below).

Patients should be advised to report promptly any new or worsening respiratory symptoms.

Patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms may continue Afinitor therapy without dose adjustments.

For oncology patients, if symptoms are moderate (Grade 2), or severe (Grade 3) the use of corticosteroids may be indicated until clinical symptoms resolve.

For TSC patients: if symptoms are moderate, consideration should be given to interruption of therapy until symptoms improve. The use of corticosteroids may be indicated. Afinitor may be reinitiated at a daily dose approximately 50% lower than the dose previously administered.

For cases of TSC patients where symptoms of non-infectious pneumonitis are severe, Afinitor therapy should be discontinued and the use of corticosteroids may be indicated until clinical symptoms resolve. Afinitor may be reinitiated at a daily dose approximately 50% lower than the dose previously administered depending on the individual clinical circumstances.

For patients who require use of corticosteroids for treatment of non-infectious pneumonitis, prophylaxis for pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) may be considered.

Infections

Everolimus has immunosuppressive properties and may predispose patients to bacterial, fungal, viral or protozoal infections, including infections with opportunistic pathogens (see section 4.8). Localised and systemic infections, including pneumonia, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) and viral infections including reactivation of hepatitis B virus, have occurred in patients taking Afinitor. Some of these infections have been severe (e.g. leading to sepsis, respiratory or hepatic failure) and occasionally fatal.

Physicians and patients should be aware of the increased risk of infection with Afinitor. Pre-existing infections should be treated appropriately and should have resolved fully before

starting treatment with Afinitor. While taking Afinitor, be vigilant for symptoms and signs of infection; if a diagnosis of infection is made, institute appropriate treatment promptly and consider interruption or discontinuation of Afinitor.

If a diagnosis of invasive systemic fungal infection is made, the Afinitor treatment should be promptly and permanently discontinued and the patient treated with appropriate antifungal therapy

Cases of pneumocystis jirovecii (carinii) pneumonia (PJP, PCP), some with fatal outcome, have been reported in patients who received everolimus. PJP/PCP may be associated with concomitant use of corticosteroids or other immunosuppressive agents. Prophylaxis for PJP/PCP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required.

Hypersensitivity reactions

Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnoea, flushing, chest pain or angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus (see section 4.3).

Concomitant use of angiotensin-converting enzyme (ACE) inhibitors

Patients taking concomitant ACE inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment). (See section 4.5)

Oral ulceration

Mouth ulcers, stomatitis, and oral mucositis have been observed in patients treated with Afinitor (see section 4.8). In such cases topical treatments are recommended, but mouthwashes containing alcohol, hydrogen-peroxide, iodine and thyme derivatives should be avoided as they may exacerbate the condition. Antifungal agents should not be used unless fungal infection has been diagnosed (see section 4.5)

Haemorrhage

Serious cases of haemorrhage, some with a fatal outcome, have been reported in patients treated with everolimus in the oncology setting. No serious cases of renal haemorrhage were reported in the TSC setting.

Caution is advised in patients taking Afinitor, particularly during concomitant use with active substances known to affect platelet function or that can increase the risk of haemorrhage as well as in patients with a history of bleeding disorders. Healthcare professionals and patients should be vigilant for signs and symptoms of bleeding throughout the treatment period, especially if risk factors for haemorrhage are combined.

Renal failure events

Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with Afinitor (see section 4.8). Renal function of patients should be monitored particularly where patients have additional risk factors that may further impair renal function.

Laboratory tests and monitoring

Renal function

Elevations of serum creatinine, usually mild, and proteinuria have been reported in patients treated with Afinitor (see section 4.8). Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of Afinitor therapy and periodically thereafter.

Blood glucose

Hyperglycaemia has been reported in patients taking Afinitor (see section 4.8). Monitoring of fasting serum glucose is recommended prior to the start of Afinitor therapy and periodically thereafter. More frequent monitoring is recommended when Afinitor is co-administered with other medical products that may induce hyperglycemia. When possible optimal glycaemic control should be achieved before starting a patient on Afinitor.

Blood lipids

Dyslipidemia (including hypercholesterolemia and hypertriglyceridemia) has been reported in patients taking Afinitor. Monitoring of blood cholesterol and triglycerides prior to the start of Afinitor therapy and periodically thereafter as well as management with appropriate medical therapy is recommended.

Hematological parameters

Decreased haemoglobin, lymphocytes, platelets and neutrophils have been reported (see section 4.8). Monitoring of complete blood count is recommended prior to the start of Afinitor therapy and periodically thereafter.

Functional carcinoid tumours

In a randomised, double-blind, multi-centre trial in patients with functional carcinoid tumours, Afinitor plus depot octreotide was compared to placebo plus depot octreotide. The study did not meet the primary efficacy endpoint (progression-free-survival [PFS]) and the overall survival (OS) interim analysis numerically favoured the placebo plus depot octreotide arm. Therefore, the safety and efficacy of Afinitor in patients with functional carcinoid tumours have not been established.

Prognostic factors in neuroendocrine tumours of gastrointestinal or lung origin

In patients with non-functional gastrointestinal or lung neuroendocrine tumours and good prognostic baseline factors, e.g. ileum as primary tumour origin and normal chromogranin A values or without bone involvement, an individual benefit-risk assessment should be performed prior to the start of Afinitor therapy. A limited evidence of PFS benefit was reported in the subgroup of patients with ileum as primary tumour origin (see section 5.1).

Interactions

Co-administration with inhibitors and inducers of CYP3A4 and/or the multidrug efflux pump P-glycoprotein (PgP) should be avoided. If co-administration of a **moderate** CYP3A4 and/or PgP inhibitor or inducer cannot be avoided, dose adjustments of Afinitor for oncology patients can be taken into consideration based on predicted AUC, dose adjustments of Afinitor for TSC patients may also be required. (see section 4.5).

Concomitant treatment with **potent** CYP3A4 inhibitors result in dramatically increased blood concentrations of everolimus (see section 4.5). There are currently not sufficient data to allow dosing recommendations in this situation. Hence, concomitant treatment of Afinitor and **potent** inhibitors is not recommended.

Caution should be exercised when Afinitor is taken in combination with orally administered CYP3A4 substrates with a narrow therapeutic index due to the potential for drug interactions. If Afinitor is taken with orally administered CYP3A4 substrates with a narrow therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine or ergot alkaloid derivatives), the patient should be monitored for undesirable effects described in the product information of the orally administered CYP3A4 substrate (see section 4.5).

Hepatic impairment

Oncology patients:

Exposure to everolimus was increased in patients with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) hepatic impairment (see section 5.2).

Afinitor is only recommended for use in patients with severe hepatic impairment (Child-Pugh C) if the potential benefit outweighs the risk (see sections 4.2 and 5.2).

No clinical safety or efficacy data are currently available to support dose adjustment recommendations for the management of adverse reactions in oncology patients with hepatic impairment.

TSC patients:

Afinitor is not recommended for use in patients:

- with **renal angiomyolipoma** associated with TSC and concomitant severe hepatic impairment (Child-Pugh C) unless the potential benefit outweighs the risk (see sections 4.2 and 5.2).
- **≥18 years of age with SEGA** and concomitant severe hepatic impairment (Child-Pugh C) (see sections 4.2 and 5.2).
- **<18 years of age with SEGA** and concomitant hepatic impairment (Child-Pugh A, B and C) (see sections 4.2 and 5.2).

Vaccinations

The use of live vaccines should be avoided during treatment with Afinitor (see section 4.5).

For pediatric patients with SEGA who do not require immediate treatment, completion of the recommended childhood series of live virus vaccinations is advised prior to the start of therapy according to local treatment guidelines.

Lactose

Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Wound healing complications

Impaired wound healing is a class effect of rapamycin derivatives, including Afinitor. Caution should therefore be exercised with the use of Afinitor in the peri-surgical period.

4.5 Interaction with other medicinal products and other forms of interaction

Everolimus is a substrate of CYP3A4, and also a substrate and moderate inhibitor of PgP. Therefore, absorption and subsequent elimination of everolimus may be influenced by products that affect CYP3A4 and/or PgP. *In vitro*, everolimus is a competitive inhibitor of CYP3A4 and a mixed inhibitor of CYP2D6.

Known and theoretical interactions with selected inhibitors and inducers of CYP3A4 and PgP are listed in Table 2 below.

CYP3A4 and PgP inhibitors increasing everolimus concentrations

Substances that are inhibitors of CYP3A4 or PgP may increase everolimus blood concentrations by decreasing metabolism or the efflux of everolimus from intestinal cells.

CYP3A4 and PgP inducers decreasing everolimus concentrations

Substances that are inducers of CYP3A4 or PgP may decrease everolimus blood concentrations by increasing metabolism or the efflux of everolimus from intestinal cells.

Table 2 Effects of other active substances on everolimus

Active substance by interaction	Interaction – Change in Everolimus AUC/C _{max} Geometric mean ratio (observed range)	Recommendations concerning co-administration
Potent CYP3A4/PgP inhibitors		
Ketoconazole	AUC ↑15.3-fold (range 11.2-22.5) C _{max} ↑4.1-fold (range 2.6-7.0)	Concomitant treatment of Afinitor and potent inhibitors is not recommended.
Itraconazole, posaconazole, voriconazole	Not studied. Large increase in everolimus concentration is expected.	
Telithromycin, clarithromycin		
Nefazodone		
Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir		
Moderate CYP3A4/PgP inhibitors		
Erythromycin	AUC ↑4.4-fold (range 2.0-12.6) C _{max} ↑2.0-fold (range 0.9-3.5)	Use caution when co-administration of moderate CYP3A4 inhibitors or PgP inhibitors cannot be avoided. <i>Oncology patient and patients with renal angiomyolipoma associated with TSC:</i> If patients require co-administration of a moderate CYP3A4 or PgP inhibitor, dose reduction to 5 mg daily or 2.5 mg daily may be considered. However, there are no clinical data with this dose adjustment. Due to between subject variability the recommended dose
Imatinib	AUC ↑ 3.7-fold C _{max} ↑ 2.2-fold	
Verapamil	AUC ↑3.5-fold (range 2.2-6.3) C _{max} ↑2.3-fold (range 1.3-3.8)	
Ciclosporin oral	AUC ↑2.7-fold (range 1.5-4.7) C _{max} ↑1.8-fold (range 1.3-2.6)	
Fluconazole	Not studied. Increased exposure expected.	
Diltiazem		
Dronedarone	Not studied. Increased exposure expected.	

<p>Amprenavir, fosamprenavir</p>	<p>Not studied. Increased exposure expected.</p>	<p>adjustments may not be optimal in all individuals, therefore close monitoring of side effects is recommended.</p> <p>If the moderate inhibitor is discontinued, consider a washout period of at least 2 to 3 days (average elimination time for most commonly used moderate inhibitors) before the Afinitor dose is returned to the dose used prior to initiation of the co-administration. (see also Therapeutic drug monitoring in section 4.2).</p> <p><i>For patients with SEGA associated with TSC:</i></p> <p>If patients require co-administration of a moderate CYP3A4 or PgP inhibitor, reduce the daily dose by approximately 50%. Further dose reduction may be required to manage adverse reactions (see sections 4.2 and 4.4). Everolimus trough concentrations should be assessed approximately 2 weeks after the addition of a moderate CYP3A4 or PgP inhibitor. If the moderate inhibitor is discontinued, consider a washout period of at least 2 to 3 days (average elimination time for most commonly used moderate inhibitors) before the Afinitor dose is returned to the dose used prior to initiation of the co-administration. The everolimus trough concentration should be assessed approximately 2 weeks after any change in dose (see sections 4.2 and 4.4)</p>
<p>Grapefruit juice or</p>	<p>Not studied. Increased</p>	<p>Combination should be avoided.</p>

other food affecting CYP3A4/PgP	exposure expected (the effect varies widely).	
Potent and moderate CYP3A4 inducers		
Rifampicin	AUC ↓63% (range 0-80%) C _{max} ↓58% (range 10-70%)	Avoid the use of concomitant potent CYP3A4 inducers. <i>For oncology patients and patients with renal angiomyolipoma associated with TSC:</i>
Dexamethasone	Not studied. Decreased exposure expected.	If patients require co-administration of a potent CYP3A4 inducer, a Afinitor dose increase from 10 mg daily up to 20 mg daily should be considered using 5 mg increments or less applied on Day 4 and 8 following start of the inducer. This dose of Afinitor is predicted to adjust the AUC to the range observed without inducers. However, there are no clinical data with this dose adjustment. If treatment with the inducer is discontinued, consider a washout period of at least 3 to 5 days (reasonable time for significant enzyme de-induction) before the Afinitor dose is returned to the dose used prior to initiation of the co-administration (see also Therapeutic drug monitoring in section 4.2). <i>For patients with SEGA associated with TSC:</i> Patients receiving concomitant potent CYP3A4 inducers may require an increased Afinitor dose to achieve the same exposure as patients not taking potent inducers. Dosing should be titrated to attain trough concentrations of 5 to 15 ng/ml. If concentrations are below 5 ng/ml, the daily dose may
Antiepileptic agents (e.g. carbamazepine, phenobarbital, phenytoin)	Not studied. Decreased exposure expected.	
Efavirenz, nevirapine	Not studied. Decreased exposure expected.	

		be increased by 2.5 mg every 2 weeks, checking the trough level and assessing tolerability before increasing the dose. If the potent inducer is discontinued, consider a washout period of at least 3 to 5 days (reasonable time for significant enzyme de-induction) before the Afinitor dose is returned to the dose used prior to initiation of the co-administration. The everolimus trough concentrations should be assessed approximately 2 weeks after any change in dose (see sections 4.2 and 4.4)
St John's Wort (<i>Hypericum perforatum</i>)	Not studied. Large decrease in exposure expected.	Preparations containing St John's Wort should not be used during treatment with everolimus

Agents whose plasma concentration may be altered by everolimus

Based on *in vitro* results, the systemic concentrations obtained after oral daily doses of 10 mg make inhibition of PgP, CYP3A4 and CYP2D6 unlikely. However, inhibition of CYP3A4 and PgP in the gut cannot be excluded. An interaction study in healthy subjects demonstrated that co-administration of an oral dose of midazolam, a sensitive CYP3A substrate probe, with everolimus resulted in a 25% increase in midazolam C_{max} and a 30% increase in midazolam $AUC_{(0-inf)}$. The effect is likely to be due to inhibition of intestinal CYP3A4 by everolimus. Hence everolimus may affect the bioavailability of orally co-administered CYP3A4 substrates. However, a clinically relevant effect on the exposure of systemically administered CYP3A4 substrates is not expected (see section 4.4).

Co-administration of everolimus and depot octreotide increased octreotide C_{min} with a geometric mean ratio (everolimus/placebo) of 1.47. A clinically significant effect on the efficacy response to everolimus in patients with advanced neuroendocrine tumours could not be established.

Co-administration of everolimus and exemestane increased exemestane C_{min} and C_{2h} by 45% and 64%, respectively. However, the corresponding oestradiol levels at steady state (4 weeks) were not different between the two treatment arms. No increase in adverse events related to exemestane was observed in patients with hormone receptor-positive advanced breast cancer receiving the combination. The increase in exemestane levels is unlikely to have an impact on efficacy or safety.

Concomitant use of angiotensin-converting enzyme (ACE) inhibitors

Patients taking concomitant ACE inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (see section 4.4).

Vaccinations

The immune response to vaccination may be affected and, therefore, vaccination may be less effective during treatment with Afinitor. The use of live vaccines should be avoided during treatment with Afinitor (see section 4.4). Examples of live vaccines are: intranasal influenza, measles, mumps, rubella, oral polio, BCG (Bacillus Calmette-Guérin), yellow fever, varicella, and TY21a typhoid vaccines.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/ Contraception in males and females

Women of childbearing potential must use a highly effective method of contraception (e.g. oral, injected, or implanted non-oestrogen-containing hormonal method of birth control, progesterone-based contraceptives, hysterectomy, tubal ligation, complete abstinence, barrier methods, intrauterine device [IUD], and/or female/male sterilisation) while receiving Afinitor, and for up to 8 weeks after ending treatment.

Male patients should not be prohibited from attempting to father children.

Pregnancy

There are no adequate data from the use of Afinitor in pregnant women. Studies in animals have shown reproductive toxicity effects including embryo-toxicity and fetotoxicity (see section 5.3). The potential risk for humans is unknown.

Afinitor is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is not known whether everolimus is excreted in breast milk. However, in rats, everolimus and/or its metabolites readily pass into the milk (see section 5.3). Therefore women taking Afinitor should not breast-feed.

Fertility

The potential for everolimus to cause infertility in male and female patients is unknown. However, amenorrhoea (secondary amenorrhoea and other menstrual irregularities) and associated luteinising hormone (LH)/follicle stimulating hormone (FSH) imbalance has been observed in female patients.

Based on non-clinical findings, male and female fertility may be compromised by treatment with Afinitor (see section 5.3).

4.7 Effects on ability to drive and use machines

Afinitor may have a minor or moderate influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines if they experience fatigue during treatment with Afinitor.

4.8 Undesirable effects

Oncology patients - Summary of safety profile

The safety profile is based on pooled data from 2,672 patients treated with Afinitor in ten clinical studies consisting of five randomized, double-blind, placebo controlled phase -III studies and five open-label phase I and phase-II studies related to the approved indications in oncology.

The most common adverse reactions (incidence $\geq 1/10$) from the pooled safety data were (in decreasing order): stomatitis, rash, fatigue, diarrhoea, infections, nausea, decreased appetite, anemia, dysgeusia, pneumonitis, oedema peripheral, hyperglycemia, asthenia, pruritus, weight decreased, hypercholesterolemia, epistaxis, cough and headache.

The most frequent Grade 3-4 adverse reactions (incidence $\geq 1/100$ to $< 1/10$) were stomatitis, anemia, hyperglycemia, infections, fatigue, diarrhea, pneumonitis, asthenia, thrombocytopenia, neutropenia, dyspnea, proteinuria, lymphopenia, hemorrhage, hypophosphatemia, rash, hypertension, pneumonia, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, and diabetes mellitus. The grades follow CTCAE Version 3.0 and 4.03.

Tabulated list of adverse reactions in oncology

Table 3 presents the frequency category of adverse reactions reported in the pooled analysis considered for the safety pooling.

Adverse reactions are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 3 Adverse reactions reported in oncology clinical studies

Infections and infestations	
Very common	Infections ^{a*}
Blood and lymphatic system disorders	
Very common	Anemia
Common	Thrombocytopenia, neutropenia, leukopenia, lymphopenia
Uncommon	Pancytopenia

Rare	pure red cell aplasia
Immune system disorders	
Uncommon	Hypersensitivity
Metabolism and nutrition disorders	
Very common	Decreased appetite, hyperglycemia, hypercholesterolemia
Common	Hypertriglyceridemia, hypophosphatemia, diabetes mellitus, hyperlipidemia, hypokalemia, dehydration, hypocalcaemia
Psychiatric disorders	
Common	Insomnia
Nervous system disorders	
Very common	Dysgeusia, headache
Uncommon	Ageusia
Eye disorders	
Common	eyelid oedema
uncommon	Conjunctivitis
Cardiac disorders	
Uncommon	Congestive cardiac failure
Vascular disorders	
Common	Hemorrhage ^b , hypertension.
Uncommon	Flushing, Deep vein thrombosis
Respiratory, thoracic and mediastinal disorders	
Very common	Pneumonitis ^c , epistaxis, cough
Common	Dyspnea
Uncommon	Hemoptysis, pulmonary embolism
Rare	Acute respiratory distress syndrome
Gastrointestinal disorders	
Very common	Stomatitis ^d , diarrhea, nausea
Common	Vomiting, dry mouth, abdominal pain, mucosal inflammation, oral pain, dyspepsia, dysphagia
Hepatobiliary disorders	
common	Aspartate aminotransferase increased, alanine aminotransferase increased

Skin and subcutaneous tissue disorders	
Very common	Rash, pruritus
Common	Dry skin, nail disorder, mild alopecia, acne, erythema, onychoclasia, hand-foot syndrome, skin exfoliation, skin lesion
Rare	Angioedema
Musculoskeletal and connective tissue disorders	
Common	Arthralgia
Renal and urinary disorders	
Common	Proteinuria*, blood creatinine increased* renal failure*
Uncommon	Increased daytime urination, acute renal failure
Reproductive system and breast disorders	
Common	Menstruation irregular ^c
Uncommon	Amenorrhea ^c
General disorders and administration site conditions	
Very common	Fatigue, asthenia, oedema peripheral
Common	Pyrexia
Uncommon	Non-cardiac chest pain, impaired wound healing
Investigations	
Very common	Weight decreased

**See also subsection "Description of selected adverse reactions"*

^a Includes all reactions within the 'infections and infestations' system organ class including (common): pneumonia, urinary tract infection; (uncommon): bronchitis, herpes zoster, sepsis, abscess, and isolated cases of opportunistic infections [e.g. aspergillosis, candidiasis pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) and hepatitis B (see also section 4.4)] and (rare) viral myocarditis.

^b Includes different bleeding events from different sites not listed individually

^c Includes (common) pneumonitis, interstitial lung disease, lung infiltration; and (rare): pulmonary alveolar hemorrhage, pulmonary toxicity and alveolitis

^d Includes (very common) stomatitis, (common) aphthous stomatitis, mouth and tongue ulceration and (uncommon) glossodynia , glossitis

^e Frequency based upon number of women from 10 to 55 years of age in the pooled data

Tuberous sclerosis complex (TSC)

Summary of the safety profile

Two randomised, double-blind, placebo-controlled pivotal phase III studies and a phase II study contribute to the safety profile of Afinitor.

- **EXIST-2 (CRAD001M2302):** This was a randomised, double-blind, controlled, phase III trial of everolimus (n=79) versus placebo (n=39) in patients with either TSC plus renal angiomyolipoma (n=113) or sporadic lymphangiomyomatosis (LAM) plus renal angiomyolipoma (n=5). The median duration of blinded study treatment was 48.1 weeks (range 2 to 115) for patients receiving Afinitor and 45.0 weeks (range 9 to 115) for those receiving placebo. No difference was evident between the two arms as regards the proportion of patients who discontinued because of ADRs (2.5% on everolimus versus 2.6% on placebo). The cumulative exposure to Afinitor (112 patients who took at least one dose of everolimus) up to a median duration of exposure of 204.1 weeks (range 2 to 278) was associated with a discontinuation rate due to ADRs of 7.1% (n=8/112).
- **EXIST-1 (CRAD001M2301):** This was a randomised, double-blind, controlled, phase III trial of everolimus (n=78) versus placebo (n=39) in patients with TSC who have SEGA, irrespective of age. The median duration of blinded study treatment was 52.2 weeks (range 24 to 89) for patients receiving Afinitor and 46.6 weeks (range 14 to 88) for those receiving placebo. No patients discontinued study drug because of ADRs during the blinded study treatment phase. The cumulative exposure to Afinitor (111 patients who took at least one dose of everolimus) up to a median duration of exposure of 204.9 weeks (range 8.1 to 253.7) was associated with a discontinuation rate due to ADRs of 7.2% (n=8/111).

- CRAD001C2485: This was a prospective, open-label, single-arm phase II study of everolimus in patients with SEGA (n=28). The median duration of exposure was 67.8 months (range 4.7 to 83.2). No patients discontinued study drug due to ADRs.

The most frequent adverse reactions (incidence $\geq 1/10$ and suspected by the investigator to be related to treatment) from the pooled safety data are (in decreasing order): stomatitis, upper respiratory tract infections, amenorrhoea, hypercholesterolaemia, nasopharyngitis, acne, menstruation irregular, sinusitis, otitis media and pneumonia.

The most frequent grade 3-4 adverse reactions (incidence $\geq 1\%$) were stomatitis, amenorrhoea, pneumonia, neutropenia, pyrexia, gastroenteritis viral and cellulitis. The grades follow CTCAE Version 3.0.

Tabulated summary of adverse reactions

Table 3-1 shows the incidence of adverse reactions based on pooled data of patients receiving everolimus in the three TSC studies (including both the double-blind and open-label extension phase, where applicable). Adverse reactions are listed according to MedDRA system organ class. Frequency categories are defined using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 3-1 Adverse reactions reported in TSC studies

Infections and infestations	
Very common	Upper respiratory tract infection, nasopharyngitis, sinusitis, , otitis media , pneumonia ^a
Common	Urinary tract infection, pharyngitis, cellulitis, pharyngitis streptococcal, gastroenteritis viral, gingivitis, herpes zoster
Uncommon	bronchitis viral
Blood and lymphatic system disorders	
Common	Neutropenia, anemia, leukopenia, lymphopenia, thrombocytopenia,
Immune system disorders	
Uncommon	Hypersensitivity
Metabolism and nutrition disorders	
Very common	Hypercholesterolemia
Common	Hyperlipidemia, decreased appetite, hypertriglyceridemia, hypophosphatemia, hyperglycemia

Psychiatric disorders	
Common	Irritability, aggression
Uncommon	Insomnia
Nervous system disorders	
Common	Headache, dysgeusia
Vascular disorders	
Common	Hypertension, lymphedema
Respiratory, thoracic and mediastinal disorders	
Common	Cough, epistaxis, pneumonitis
Gastrointestinal disorders	
Very common	Stomatitis ^b
Common	Diarrhoea, nausea, vomiting, abdominal pain, oral pain, flatulence, constipation, gastritis
Skin and subcutaneous tissue disorders	
Very Common	Acne
Common	Rash ^c , acneiform dermatitis, dry skin, pruritus, alopecia
Uncommon	Angioedema
Musculoskeletal and connective tissue disorders	
Uncommon	Rhabdomyolysis
Renal and urinary disorders	
Common	Proteinuria
Reproductive system and breast disorders	
Very Common	Amenorrhea ^d , menstruation irregular ^d
Common	Vaginal hemorrhage, menorrhagia, ovarian cyst, menstruation delayed ^d
General disorders and administration site conditions	
Common	Fatigue, pyrexia
Investigations	

Common	Blood lactate dehydrogenase increased, blood luteinizing hormone increased, weight decreased
Uncommon	Blood follicle stimulating hormone increased
^a Includes pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) ^b Includes (very common) stomatitis, mouth ulceration; aphthous stomatitis and (uncommon) gingival pain, glossitis, lip ulceration, tongue ulceration. ^c Includes (common) rash, rash erythematous erythema and (uncommon) rash macular, rash maculo-papular, rash generalized. ^d frequency is based upon number of women from 10 to 55 years of age while on treatment in the pooled data	

Description of selected adverse reactions

In clinical studies and post-marketing spontaneous reports, everolimus has been associated with serious cases of hepatitis B reactivation, including fatal outcome. Reactivation of infection is an expected reaction during periods of immunosuppression.

In clinical studies and post-marketing spontaneous reports, everolimus has been associated with renal failure events (including fatal outcome), proteinuria and increased serum creatinine. Monitoring of renal function is recommended (see section 4.4).

In clinical studies for TSC indications, everolimus has been associated with haemorrhage events. On rare occasions, fatal outcomes were observed in the oncology setting (see section 4.4). No serious cases of renal haemorrhage were reported in the TSC setting. In clinical studies for oncology indications and post-marketing spontaneous reports, everolimus has been associated with cases of amenorrhoea (secondary amenorrhoea and other menstrual irregularities).

In clinical studies and post-marketing spontaneous reports, everolimus has been associated with cases of pneumocystis jirovecii (carinii) pneumonia (PJP, PCP), some with fatal outcome (see section 4.4).

Additional adverse reactions of relevance observed in oncology clinical studies and post-marketing spontaneous reports, were cardiac failure, pulmonary embolism, deep vein thrombosis, impaired wound healing and hyperglycaemia.

In clinical trials and post-marketing spontaneous reports, angioedema has been reported with and without concomitant use of ACE inhibitors (see section 4.4).

Paediatric population

In the pivotal phase II study, 22 of the 28 SEGA patients studied were below the age of 18 years and in the pivotal phase III study, 101 of the 117 SEGA patients studied were below the age of 18 years. In both studies, frequency, type and severity of adverse reactions observed in children and adolescents have been generally consistent with those observed in adults. With the exception of infections which were reported at a higher frequency, especially in children below the age of 3 years.

Elderly patients

In the oncology safety pooling, 37% of the patients treated with everolimus were ≥ 65 years of age. The number of oncology patients with an adverse reaction leading to discontinuation of everolimus was higher in patients ≥ 65 years of age (20% vs. 13%). The most common adverse reactions leading to discontinuation were pneumonitis (including interstitial lung disease), fatigue, dyspnoea, and stomatitis.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

(<http://forms.gov.it/globaldata/getsequence/getsequence.aspx?formType=AdversEffe ctMedic@moh.gov.it>).

4.9 Overdose

Reported experience with overdose in humans is very limited. Single doses of up to 70 mg have been given with acceptable acute tolerability.

It is essential to assess everolimus blood levels in cases of suspected overdose. General supportive measures should be initiated in all cases of overdose. Everolimus is not considered dialysable to any relevant degree (less than 10% was removed within 6 hours of haemodialysis).

Paediatric population

A limited number of TSC paediatric patients have been exposed to doses higher than 10 mg/m²/day. No signs of acute toxicity have been reported in these cases.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, protein kinase inhibitors, ATC code: L01XE10

Mechanism of action

Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. Everolimus binds to the intracellular protein FKBP-12, forming a complex that inhibits mTOR complex-1 (mTORC1) activity. Inhibition of the mTORC1 signalling pathway interferes with the translation and synthesis of proteins by reducing the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4EBP-1) that regulate proteins involved in the cell cycle, angiogenesis and glycolysis. S6K1 is thought to phosphorylate the activation function domain 1 of the oestrogen receptor, which is responsible for ligand-independent receptor activation. Everolimus reduces levels of vascular endothelial growth factor (VEGF), which potentiates tumour angiogenic processes. In patients with TSC, treatment with everolimus increases VEGF-A and decreases VEGF-D levels. Everolimus is a potent inhibitor of the growth and proliferation of tumour cells, endothelial cells, fibroblasts and blood-vessel-associated smooth muscle cells and has been shown to reduce glycolysis in solid tumours *in vitro* and *in vivo*.

Two primary regulators of mTORC1 signaling are the oncogene suppressors tuberlin-sclerosis complexes 1 & 2 (TSC1, TSC2). Loss of either TSC1 or TSC2 leads to elevated rheb-GTP levels, a ras family GTPase, which interacts with the mTORC1 complex to cause its activation. mTORC1 activation leads to a downstream kinase signaling cascade, including activation of the S6 kinase. In tuberous sclerosis complex syndrome, inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body. TSC1 mutations account for 20–25% of all mutations identified, and TSC2 mutations account for the remainder.

In a mouse neuronal model of TSC in which TSC1 is ablated in most neurons during cortical development, everolimus improved median survival from 33 days to more than 100 days, and behaviour, phenotype, and weight gain all also markedly improved. There was brain penetration, with accumulation over time with repetitive treatment, and effective reduction of levels of phospho-S6, a downstream marker of mTORC1. Neurofilament abnormalities, myelination and cell enlargement were all improved by the treatment, although dysplastic neuronal features persisted, and there were only modest changes in dendritic spine density and length. Strikingly, mice treated with everolimus for 23 days only (postnatal days 7–30) displayed a persistent improvement in phenotype, with median survival of 78 days. In summary, everolimus is a highly effective therapy for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signalling and, consequently,

cell size and myelination. Although caution is appropriate, the results suggest the possibility that everolimus may have benefit in the treatment of TSC brain disease, including infantile spasms.

Clinical efficacy and safety in oncology

Hormone receptor-positive advanced breast cancer

BOLERO-2 (study CRAD001Y2301), a randomised, double-blind, multicentre phase III study of Afinitor + exemestane versus placebo + exemestane, was conducted in postmenopausal women with oestrogen receptor-positive, HER2/neu negative advanced breast cancer with recurrence or progression following prior therapy with letrozole or anastrozole.

Randomisation was stratified by documented sensitivity to prior hormonal therapy and by the presence of visceral metastasis. Sensitivity to prior hormonal therapy was defined as either (1) documented clinical benefit (complete response [CR], partial response [PR], stable disease \geq 24 weeks) from at least one prior hormonal therapy in the advanced setting or (2) at least 24 months of adjuvant hormonal therapy prior to recurrence.

The primary endpoint for the study was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria in Solid Tumors), based on the investigator's assessment (local radiology). Supportive PFS analyses were based on an independent central radiology review.

Secondary endpoints included overall survival (OS), objective response rate, clinical benefit rate, safety, change in quality of life (QoL) and time to ECOG PS (Eastern Cooperative Oncology Group performance status) deterioration.

A total of 724 patients were randomised in a 2:1 ratio to the combination everolimus (10 mg daily) + exemestane (25 mg daily) (n=485) or to the placebo + exemestane arm (25 mg daily) (n=239).


At the time of the final OS analysis, the median duration of everolimus treatment was 24.0 weeks (range 1.0-199.1 weeks). The median duration of exemestane treatment was longer in the everolimus + exemestane group at 29.5 weeks (1.0-199.1) compared to 14.1 weeks (1.0-156.0) in the placebo + exemestane group.

The efficacy results for the primary endpoint were obtained from the final PFS analysis (see Table 4 and Figure 1). Patients in the placebo + exemestane arm did not cross over to everolimus at the time of progression.

Table 4 BOLERO-2 efficacy results

Analysis	Afinitor^a n=485	Placebo^a n=239	Hazard ratio	p value
Median progression-free survival (months) (95% CI)				
Investigator radiological review	-7.8 (6.9 to 8.5)	3.2 (2.8 to 4.1)	0.45 (0.38 to 0.54)	<0.0001
Independent radiological review	11.0 (9.7 to 15.0)	4.1 (2.9 to 5.6)	0.38 (0.31 to 0.48)	<0.0001
Median overall survival (months) (95% CI)				
Median overall survival	31.0 (28.0 – 34.6)	26.6 (22.6 – 33.1)	0.89 (0.73 – 1.10)	0.1426
Best overall response (%) (95% CI)				
Objective response rate ^b	12.6% (9.8 to 15.9)	1.7% (0.5 to 4.2)	n/a ^d	<0.0001 ^e
Clinical benefit rate ^c	51.3% (46.8 to 55.9)	26.4% (20.9 to 32.4)	n/a ^d	<0.0001 ^e
^a Plus exemestane ^b Objective response rate = proportion of patients with complete or partial response ^c Clinical benefit rate = proportion of patients with complete or partial response or stable disease ≥24 weeks ^d Not applicable ^e p value is obtained from the exact Cochran-Mantel-Haenszel test using a stratified version of the Cochran-Armitage permutation test.				

Figure 1 BOLERO-2 Kaplan-Meier progression-free survival curves (investigator radiological review)



Number of Patients still at Risk																					
Time(weeks)	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96	102	108	114	120
Everolimus	485	436	366	304	257	221	185	158	124	91	66	50	35	24	22	13	10	8	2	1	0
Placebo	239	190	132	96	67	50	39	30	21	15	10	8	5	3	1	1	1	0	0	0	0

The estimated PFS treatment effect was supported by planned subgroup analysis of PFS per investigator assessment. For all analysed subgroups (age, sensitivity to prior hormonal therapy, number of organs involved, status of bone-only lesions at baseline and presence of visceral metastasis, and across major demographic and prognostic subgroups) a positive treatment effect was seen with everolimus + exemestane with an estimated hazard ratio versus placebo + exemestane ranging from 0.25 to 0.60

No differences in the time to $\geq 5\%$ deterioration in the global and functional domain scores of QLQ-C30 were observed in the two arms.

Advanced neuroendocrine tumours of pancreatic origin (pNET)

RADIANT-3 (study CRAD001C2324), a phase III, multicentre, randomised, double-blind study of Afinitor plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumor (pNET), demonstrated a statistically significant clinical benefit of Afinitor over placebo by a 2.4-fold prolongation of median progression-free-survival (PFS) (11.04 months versus 4.6 months), (HR 0.35; 95% CI: 0.27, 0.45; $p < 0.0001$) (see Table 5 and Figure 2).

RADIANT-3 involved patients with well- and moderately-differentiated advanced pNET whose disease had progressed within the prior 12 months. Treatment with somatostatin analogues was allowed as part of BSC.

The primary endpoint for the study was PFS evaluated by RECIST (Response Evaluation Criteria in Solid Tumors) Following documented radiological progression, patients could be unblinded by the investigator. Those randomised to placebo were then able to receive open-label Afinitor.

Secondary endpoints included safety, objective response rate), response duration and overall survival (OS).


In total, 410 patients were randomised 1:1 to receive either Afinitor 10 mg/day (n=207) or placebo (n=203). Demographics were well balanced (median age 58 years, 55% male, 78.5% Caucasian). Fifty-eight percent of the patients in both arms received prior systemic therapy. The median duration of blinded study treatment was 37.8 weeks (range 1.1-129.9 weeks) for patients receiving everolimus and 16.1 weeks (range 0.4-147.0 weeks) for those receiving placebo.

Following disease progression or after study unblinding, 172 of the 203 patients (84.7%) initially randomised to placebo crossed over to open-label Afinitor. The median duration of open-label treatment was 47.7 weeks among all patients; 67.1 weeks in the 53 patients randomised to everolimus who switched to open-label everolimus and 44.1 weeks in the 172 patients randomised to placebo who switched to open-label everolimus.

Table 5 RADIANT-3 – efficacy results

Population	Afinitor n=207	Placebo n=203	Hazard ratio (95% CI)	p-value
Median progression-free survival (months) (95% CI)				
Investigator radiological review	11.04 (8.41, 13.86)	4.60 (3.06, 5.39)	0.35 (0.27, 0.45)	<0.0001
Independent radiological review	13.67 (11.17, 18.79)	5.68 (5.39, 8.31)	0.38 (0.28, 0.51)	<0.0001
Median overall survival (months) (95% CI)				
Median overall survival	44.02 (35.61, 51.75)	37.68 (29.14, 45.77)	0.94 (0.73, 1.20)	0.300

Figure 2 RADIANT-3 – Kaplan-Meier progression-free survival curves (investigator radiological review)



Advanced neuroendocrine tumours of gastrointestinal or lung origin

RADIANT-4 (study CRAD001T2302), a randomised, double-blind, multicentre, phase III study of Afinitor plus best supportive care (BSC) versus placebo plus BSC was conducted in patients with advanced, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin without a history of and no active symptoms related to carcinoid syndrome.

The primary endpoint for the study was progression-free survival (PFS) evaluated by Response Evaluation Criteria in Solid Tumors (RECIST), based on independent radiology assessment. Supportive PFS analysis was based on local investigator review. Secondary

endpoints included overall survival (OS), overall response rate, disease control rate, safety, change in quality of life (FACT-G) and time to World Health Organisation performance status (WHO PS) deterioration.


A total of 302 patients were randomised in a 2:1 ratio to receive either everolimus (10 mg daily) (n=205) or placebo (n=97). Demographics and disease characteristics were generally balanced (median age 63 years [range 22 to 86], 76% Caucasian, history of prior somatostatin analogue [SSA] use). The median duration of blinded treatment was 40.4 weeks for patients receiving Afinitor and 19.6 weeks for those receiving placebo. Patients in the placebo arm did not cross-over to everolimus at the time of progression.

The efficacy results for the primary endpoint were obtained from the final PFS analysis (see Table 6 and Figure 3).

Table 6 RADIANT-4 – Progression-free survival results

Population	Afinitor n=205	Placebo n=97	Hazard ratio (95% CI)	p-value^a
Median progression-free survival (months) (95% CI)				
Independent radiological review	11.01 (9.2, 13.3)	3.91 (3.6, 7.4)	0.48 (0.35, 0.67)	<0.0001
Investigator radiological review	13.96 (11.2, 17.7)	5.45 (3.7, 7.4)	0.39 (0.28, 0.54)	<0.0001
^a One-sided p-value from a stratified log-rank test				

Figure 3 RADIANT-4 – Kaplan-Meier progression-free survival curves (independent radiological review)




Number of Patients still at Risk

Time(months)	0	2	4	6	8	10	12	15	18	21	24	27	30
Everolimus	205	168	145	124	101	81	65	52	26	10	3	0	0
Placebo	97	65	39	30	24	21	17	15	11	6	5	1	0

In supportive analyses, positive treatment effect has been observed in all subgroups with the exception of the subgroup of patients with ileum as primary site of tumour origin [Ileum: HR=1.22 (95% CI: 0.56 to 2.65); Non-ileum: HR=0.34 (95% CI: 0.22 to 0.54); Lung: HR=0.43 (95% CI: 0.24 to 0.79)] (see Figure 4).

Figure 4 RADIANT-4 – Progression free survival results by pre-specified patient subgroup (independent radiological review)



*Non-ileum: stomach, colon, rectum, appendix, caecum, duodenum, jejunum, carcinoma of unknown primary origin and other gastrointestinal origin
 ULN: Upper limit of normal
 CgA: Chromogranin A
 NSE: Neuron specific enolase
 Hazard ratio (95% CI) from stratified Cox model

The pre-planned OS interim analysis after 101 deaths (out of 191 required for final analysis) and 33 months follow-up favoured the everolimus arm; however, no statistically significant difference in OS was noted (HR= 0.73 [95% CI: 0.48 to 1.11; p=0.071]).

No difference in the time to definitive deterioration of WHO PS (≥1 point) and time to definitive deterioration in quality of life (FACT-G total score ≥7 points) was observed between the two arms.

Advanced renal cell carcinoma

RECORD-1 (study CRAD001C2240), a phase III, international, multicentre, randomised, double-blind study comparing everolimus 10 mg/day and placebo, both in conjunction with best supportive care, was conducted in patients with metastatic renal cell carcinoma whose disease had progressed on or after treatment with VEGFR-TKI (vascular endothelial growth factor receptor tyrosine kinase inhibitor) therapy (sunitinib, sorafenib, or both sunitinib and sorafenib). Prior therapy with bevacizumab and interferon- α was also permitted. Patients were stratified according to Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic score (favourable- vs. intermediate- vs. poor-risk groups) and prior anticancer therapy (1 vs. 2 prior VEGFR-TKIs).

Progression-free survival, documented using RECIST (Response Evaluation Criteria in Solid Tumours) and assessed via a blinded, independent central review, was the primary endpoint. Secondary endpoints included safety, objective tumour response rate, overall survival, disease-related symptoms, and quality of life. After documented radiological progression, patients could be unblinded by the investigator: those randomised to placebo were then able to receive open-label everolimus 10 mg/day. The Independent Data Monitoring Committee recommended termination of this trial at the time of the second interim analysis as the primary endpoint had been met.


In total, 416 patients were randomised 2:1 to receive Afinitor (n=277) or placebo (n=139). Demographics were well balanced (pooled median age [61 years; range 27-85], 78% male, 88% Caucasian, number of prior VEGFR-TKI therapies [1-74%, 2-26%]). The median duration of blinded study treatment was 141 days (range 19-451 days) for patients receiving everolimus and 60 days (range 21-295 days) for those receiving placebo.

Afinitor was superior to placebo for the primary endpoint of progression-free survival, with a statistically significant 67% reduction in the risk of progression or death (see Table 7 and Figure 5).

Table 7 RECORD-1 – Progression-free survival results

Population	n	Afinitor n=277	Placebo n=139	Hazard ratio (95%CI)	p-value
		Median progression-free survival (months) (95% CI)			
Primary analysis					
All (blinded independent central review)	416	4.9 (4.0-5.5)	1.9 (1.8-1.9)	0.33 (0.25-0.43)	<0.0001 ^a
Supportive/sensitivity analyses					
All (local review by investigator)	416	5.5 (4.6-5.8)	1.9 (1.8-2.2)	0.32 (0.25-0.41)	<0.0001 ^a
<i>MSKCC prognostic score (blinded independent central review)</i>					
Favourable risk	120	5.8 (4.0-7.4)	1.9 (1.9-2.8)	0.31 (0.19-0.50)	<0.0001
Intermediate risk	235	4.5 (3.8-5.5)	1.8 (1.8-1.9)	0.32 (0.22-0.44)	<0.0001
Poor risk	61	3.6 (1.9-4.6)	1.8 (1.8-3.6)	0.44 (0.22-0.85)	0.007
^a Stratified log-rank test					

Figure 5 RECORD-1 – Kaplan-Meier progression-free survival curves (independent central review)



No. of patients still at risk	0	2	4	6	8	10	12	14
Time (months)	0	2	4	6	8	10	12	14
Afinitor	277	192	115	51	26	10	1	0
Placebo	139	47	15	6	2	0	0	0

Six-month PFS rates were 36% for Afinitor therapy compared with 9% for placebo.

Confirmed objective tumour responses were observed in 5 patients (2%) receiving Afinitor, while none were observed in patients receiving placebo. Therefore, the progression-free survival advantage primarily reflects the population with disease stabilisation (corresponding to 67% of the Afinitor treatment group).

No statistically significant treatment-related difference in overall survival was noted (hazard ratio 0.87; confidence interval: 0.65-1.17; p=0.177). Crossover to open-label Afinitor following disease progression for patients allocated to placebo confounded the detection of any treatment-related difference in overall survival.

Clinical efficacy and safety in Tuberous Sclerosis complex (TSC)

Renal angiomyolipoma associated with TSC

EXIST-2 (study CRAD001M2302), a randomised, controlled phase III study was conducted to evaluate the efficacy and safety of Afinitor in patients with TSC plus renal angiomyolipoma. Presence of at least one angiomyolipoma ≥3 cm in longest diameter using CT/MRI (based on local radiology assessment) was required for entry.

The primary efficacy endpoint was angiomyolipoma response rate based on independent central radiology review. The analysis was stratified by use of enzyme-inducing antiepileptic drugs (EIAEDs) at randomisation (yes/no).

Key secondary endpoints included time to angiomyolipoma progression and skin lesion response rate.

A total of 118 patients were randomised, 79 to Afinitor 10 mg daily and 39 to placebo. Median age was 31 years (range: 18 to 61 years; 46.6% were <30 years at enrolment), 33.9% were male, and 89.0% were Caucasian. Of the enrolled patients, 83.1% had angiomyolipomas ≥ 4 cm (28.8% ≥ 8 cm), 78.0% had bilateral angiomyolipomas, and 39.0% had undergone prior renal embolisation/nephrectomy; 96.6% had skin lesions at baseline and 44.1% had target SEGAs (at least one SEGA ≥ 1 cm in longest diameter).

Results showed that the primary objective related to best overall angiomyolipoma response was met with best overall response rates of 41.8% (95% CI: 30.8, 53.4) for the Afinitor arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm ($p < 0.0001$) (Table 8).

Patients initially treated with placebo were allowed to cross over to everolimus at the time of angiomyolipoma progression and upon recognition that treatment with everolimus was superior to treatment with placebo. At the time of the final analysis (4 years following the last patient randomisation), the median duration of exposure to everolimus was 204.1 weeks (range 2 to 278). The angiomyolipoma best overall response rate had increased to 58.0% (95% CI: 48.3, 67.3), with a rate of stable disease of 30.4% (Table 8).

Among patients treated with everolimus during the study, no cases of angiomyolipoma-related nephrectomy and only one case of renal embolisation were reported.

Table 8EXIST-2 - Angiomyolipoma response

	Afinitor n=79	Primary Analysis ³ Placebo n=39	p-value	Final analysis Afinitor N=112
Primary analysis				
Angiomyolipoma response rate ^{1,2} – %	41.8	0	<0.0001	58.0
95% CI	30.8, 53.4	0.0, 9.0		48.3, 67.3
Best overall angiomyolipoma response – %				
Response	41.8	0		58.0
Stable disease	40.5	79.5		30.4
Progression	1.3	5.1		0.9
Not evaluable	16.5	15.4		10.7
¹	According to independent central radiology review			
²	Angiomyolipoma responses were confirmed with a repeat scan. Response was defined as: $\geq 50\%$ reduction in the sum of angiomyolipoma volume relative to baseline, plus absence of new angiomyolipoma ≥ 1.0 cm in longest diameter, plus no increase in renal volume $>20\%$ from nadir, plus absence of grade ≥ 2 angiomyolipoma-related bleeding.			
³	Primary analysis for double blind period			
⁴	Final analysis includes patients who crossed over from the placebo group; median duration of exposure to everolimus of 204.1 weeks			

Consistent treatment effects on angiomyolipoma response rate were observed across all subgroups evaluated (i.e. EIAED use vs. EIAED non-use, sex, age and race) at the primary efficacy analysis.

In the final analysis, reduction in angiomyolipoma volume improved with longer term treatment with Afinitor. At weeks 12, 96 and 192, $\geq 30\%$ reductions in volume were observed in 75.0%, 80.6%, and 85.2% of the treated patients, respectively. Similarly, at the same timepoints, $\geq 50\%$ reductions in volume were observed in 44.2%, 63.3%, and 68.9% of the treated patients, respectively.

Median time to angiomyolipoma progression was 11.4 months in the placebo arm and was not reached in the everolimus arm (HR 0.08; 95% CI: 0.02, 0.37; $p < 0.0001$). Progressions were observed in 3.8% of patients in the everolimus arm compared with 20.5% in the placebo arm. Estimated progression-free rates at 6 months were 98.4% for the everolimus arm and 83.4% for the placebo arm.

At the final analysis, median time to angiomyolipoma progression was not reached. Angiomyolipoma progressions were observed in 14.3% of the patients. The estimated angiomyolipoma progression-free rates at 24 months and 48 months were 91.6% and 83.1%, respectively.

At the primary analysis, skin lesion response rates of 26.0% (95% CI: 16.6, 37.2) for the Afinitor arm and 0% (95% CI: 0.0, 9.5) for the placebo arm were observed (p=0.0002). At the final analysis, the skin lesion response rate had increased to 68.2% (95% CI: 58.5, 76.9), with one patient reporting a confirmed complete clinical skin lesion response and no patients experiencing progressive disease as their best response.

In an exploratory analysis of patients with TSC with angiomyolipoma who also had SEGA, the SEGA response rate (proportion of patients with $\geq 50\%$ reduction from baseline in target lesion volumes in the absence of progression) was 10.3% in the everolimus arm in the primary analysis (versus no responses reported in the 13 patients randomised to placebo with a SEGA lesion at baseline) and increased to 48.0% in the final analysis.

Post-hoc sub-group analysis of EXIST-2 (study CRAD001M2302) carried out at time of primary analysis demonstrated that angiomyolipoma response rate is reduced below the threshold of 5 ng/ml (Table 9).

Table 9 EXIST-2 - Angiomyolipoma response rates by time-averaged C_{min} category, at primary analysis

Time-averaged C _{min} category	Number of patients	Response rate	95% confidence interval
≤ 5 ng/ml	20	0.300	0.099, 0.501
> 5 ng/ml	42	0.524	0.373, 0.675
Difference ¹		-0.224	-0.475, 0.027

¹ Difference is " ≤ 5 ng/ml" minus " > 5 ng/ml"

SEGA associated with TSC

Phase III study in SEGA patients

EXIST-1 (Study CRAD001M2301), a randomised, double-blind, multicentre phase III study of Afinitor versus placebo, was conducted in patients with SEGA, irrespective of age. Patients were randomised in a 2:1 ratio to receive either Afinitor or matching placebo. Presence of at least one SEGA lesion ≥ 1.0 cm in longest diameter using MRI (based on local radiology assessment) was required for entry. In addition, serial radiological evidence of SEGA growth, presence of a new SEGA lesion ≥ 1 cm in longest diameter, or new or worsening hydrocephalus was required for entry.

The primary efficacy endpoint was SEGA response rate based on independent central radiology review. The analysis was stratified by use of enzyme-inducing antiepileptic drugs (EIAEDs) at randomisation (yes/no).

Key secondary endpoints in hierarchical order of testing included the absolute change in frequency of total seizure events per 24-hour EEG from baseline to week 24, time to SEGA progression, and skin lesion response rate.

A total of 117 patients were randomised, 78 to Afinitor and 39 to placebo. The two treatment arms were generally well balanced with respect to demographic and baseline disease characteristics and history of prior anti-SEGA therapies. In the total population, 57.3% of patients were male and 93.2% were Caucasian. The median age for the total population was 9.5 years (age range for the Afinitor arm: 1.0 to 23.9; age range for the placebo arm: 0.8 to 26.6), 69.2% of the patients were aged 3 to <18 years and 17.1% were <3 years at enrolment.

Of the enrolled patients, 79.5% had bilateral SEGAs, 42.7% had ≥ 2 target SEGA lesions, 25.6% had inferior growth, 9.4% had evidence of deep parenchymal invasion, 6.8% had radiographic evidence of hydrocephalus, and 6.8% had undergone prior SEGA-related surgery. 94.0% had skin lesions at baseline and 37.6% had target renal angiomyolipoma lesions (at least one angiomyolipoma ≥ 1 cm in longest diameter).

The median duration of blinded study treatment was 9.6 months (range: 5.5 to 18.1) for patients receiving Afinitor and 8.3 months (range: 3.2 to 18.3) for those receiving placebo.

Results showed that Afinitor was superior to placebo for the primary endpoint of best overall SEGA response ($p < 0.0001$). Response rates were 34.6% (95% CI: 24.2, 46.2) for the Afinitor arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm (Table 10). In addition, all 8 patients on the Afinitor arm who had radiographic evidence of hydrocephalus at baseline had a decrease in ventricular volume.

Patients initially treated with placebo were allowed to cross over to everolimus at the time of SEGA progression and upon recognition that treatment with everolimus was superior to treatment with placebo. All patients receiving at least one dose of everolimus were followed until drug discontinuation or study completion. At the time of the final analysis, the median duration of exposure among all such patients was 204.9 weeks (range: 8.1 to 253.7). The best overall SEGA response rate had increased to 57.7% (95% CI: 47.9, 67.0) at the final analysis. No patient required surgical intervention for SEGA during the entire course of the study.

Table 10 **EXIST-1 – SEGA response**

	Primary analysis ³		p-value	Final analysis ⁴
	Afinitor N=78	Placebo N=39		Afinitor N=111
SEGA response rate ^{1,2} - (%)	34.6	0	<0.0001	57.7
95% CI	24.2, 46.2	0.0, 9.0		47.9, 67.0
Best overall SEGA response - (%)				
Response	34.6	0		57.7
Stable disease	62.8	92.3		39.6
Progression	0	7.7		0
Not evaluable	2.6	0		2.7

¹ according to independent central radiology review

² SEGA responses were confirmed with a repeat scan. Response was defined as: $\geq 50\%$ reduction in the sum of SEGA volume relative to baseline, plus no unequivocal worsening of non-target SEGA lesions, plus absence of new SEGA ≥ 1 cm in longest diameter, plus no new or worsening hydrocephalus

³ Primary analysis for double blind period

⁴ Final analysis includes patients who crossed over from the placebo group; median duration of exposure to everolimus of 204.9 weeks

Consistent treatment effects were observed across all subgroups evaluated (i.e. EIAED use versus EIAED non-use, sex and age) at the primary analysis.

During the double-blind period, reduction of SEGA volume was evident within the initial 12 weeks of Afinitor treatment: 29.7% (22/74) of patients had $\geq 50\%$ reductions in volume and 73.0% (54/74) had $\geq 30\%$ reductions in volume. Sustained reductions were evident at week 24, 41.9% (31/74) of patients had $\geq 50\%$ reductions and 78.4% (58/74) of patients had $\geq 30\%$ reductions in SEGA volume.

In the everolimus treated population (N=111) of the study, including patients who crossed over from the placebo group, tumour response, starting as early as after 12 weeks on everolimus, was sustained at later time points. The proportion of patients achieving at least 50% reductions in SEGA volume was 45.9% (45/98) and 62.1% (41/66) at weeks 96 and 192 after start of everolimus treatment. Similarly, the proportion of patients achieving at least 30% reductions in SEGA volume was 71.4% (70/98) and 77.3% (51/66) at weeks 96 and 192 after start of everolimus treatment.

Analysis of the first key secondary endpoint, change in seizure frequency, was inconclusive; thus, despite the fact that positive results were observed for the two subsequent secondary endpoints (time to SEGA progression and skin lesion response rate), they could not be declared formally statistically significant.

Median time to SEGA progression based on central radiology review was not reached in either treatment arm. Progressions were only observed in the placebo arm (15.4%; $p=0.0002$). Estimated progression-free rates at 6 months were 100% for the Afinitor arm and 85.7% for the placebo arm.

The long-term follow-up of patients randomised to everolimus and patients randomised to placebo who thereafter crossed over to everolimus demonstrated durable responses.

At the time of the primary analysis, Afinitor demonstrated clinically meaningful improvements in skin lesion response ($p=0.0004$), with response rates of 41.7% (95% CI: 30.2, 53.9) for the Afinitor arm and 10.5% (95% CI: 2.9, 24.8) for the placebo arm. At the final analysis, the skin lesion response rate increased to 58.1% (95% CI: 48.1, 67.7).

Phase II study in patients with SEGA

A prospective, open-label, single-arm phase II study (Study CRAD001C2485) was conducted to evaluate the safety and efficacy of Afinitor in patients with SEGA. Radiological evidence of serial SEGA growth was required for entry.

Change in SEGA volume during the core 6-month treatment phase, as assessed via an independent central radiology review, was the primary efficacy endpoint. After the core treatment phase, patients could be enrolled into an extension phase where SEGA volume was assessed every 6 months.

In total, 28 patients received treatment with Afinitor; median age was 11 years (range 3 to 34), 61% male, 86% Caucasian. Thirteen patients (46%) had a secondary smaller SEGA, including 12 in the contralateral ventricle.

Primary SEGA volume was reduced at month 6 compared to baseline ($p<0.001$ [see Table 11]). No patient developed new lesions, worsening hydrocephalus or increased intracranial pressure, and none required surgical resection or other therapy for SEGA.

Table11 Change in primary SEGA volume over time

SEGA volume (cm ³)	Independent central review						
	Baseline n=28	Month 6 n=27	Month 1 2 n=26	Month 24 n=24	Month 3 6 n=23	Month 4 8 n=24	Month 6 0 n=23
Primary tumour volume							
Mean (standard deviation)	2.45 (2.813)	1.33 (1.497)	1.26 (1.526)	1.19 (1.042)	1.26 (1.298)	1.16 (0.961)	1.24 (0.959)
Median	1.74	0.93	0.84	0.94	1.12	1.02	1.17
Range	0.49 - 14.23	0.31 - 7.98	0.29 - 8.18	0.20 - 4.63	0.22 - 6.52	0.18 - 4.19	0.21 - 4.39
Reduction from baseline							
Mean (standard deviation)		1.19 (1.433)	1.07 (1.276)	1.25 (1.994)	1.41 (1.814)	1.43 (2.267)	1.44 (2.230)
Median		0.83	0.85	0.71	0.71	0.83	0.50
Range		0.06 - 6.25	0.02 - 6.05	-0.55 - 9.60	0.15 - 7.71	0.00 - 10.96	-0.74 - 9.84
Percentage reduction from baseline, n (%)							
≥50%		9 (33.3)	9 (34.6)	12 (50.0)	10 (43.5)	14 (58.3)	12 (52.2)
≥30%		21 (77.8)	20 (76.9)	19 (79.2)	18 (78.3)	19 (79.2)	14 (60.9)
>0%		27 (100.0)	26 (100.0)	23 (95.8)	23 (100.0)	23 (95.8)	21 (91.3)
Nochange		0	0	0	0	1 (4.2)	0
Increase		0	0	1 (4.2)	0	0	2 (8.7)

The robustness and consistency of the primary analysis were supported by the:

- change in primary SEGA volume as per local investigator assessment (p<0.001), with 75.0% and 39.3% of patients experiencing reductions of ≥30% and ≥50%, respectively
- change in total SEGA volume as per independent central review (p<0.001) or local investigator assessment (p<0.001).

One patient met the pre-specified criteria for treatment success (>75% reduction in SEGA volume) and was temporarily taken off trial therapy; however, SEGA re-growth was evident at the next assessment at 4.5 months and treatment was restarted.

Long-term follow-up to a median duration of 67.8 months (range: 4.7 to 83.2) demonstrated sustained efficacy.

5.2 Pharmacokinetic properties

Absorption

In patients with advanced solid tumours, peak everolimus concentrations (C_{max}) are reached at a median time of 1 hour after daily administration of 5 and 10 mg everolimus under fasting conditions or with a light fat-free snack. C_{max} is dose-proportional between 5 and 10 mg. Everolimus is a substrate and moderate inhibitor of Pgp.

Food effect

In healthy subjects, high fat meals reduced systemic exposure to everolimus 10 mg tablets (as measured by AUC) by 22% and the peak blood concentration C_{max} by 54%. Light fat meals reduced AUC by 32% and C_{max} by 42%.

Food, however, had no apparent effect on the post absorption phase concentration-time profile 24 hours post-dose.

Relative bioavailability/bioequivalence

In a relative bioavailability study in TSC patients, AUC_{0-inf} of 5 x 1 mg everolimus tablets when administered as suspension in water was equivalent to 5 x 1 mg everolimus tablets administered as intact tablets, and C_{max} of 5 x 1 mg everolimus tablets in suspension was 72% of 5 x 1 mg intact everolimus tablets.

Distribution

The blood-to-plasma ratio of everolimus, which is concentration-dependent over the range of 5 to 5,000 ng/ml, is 17% to 73%. Approximately 20% of the everolimus concentration in whole blood is confined to plasma of cancer patients given everolimus 10 mg/day. Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment. In patients with advanced solid tumours, V_d was 191 l for the apparent central compartment and 517 l for the apparent peripheral compartment.

Nonclinical studies in rats indicate:

- A rapid uptake of everolimus in the brain followed by a slow efflux.
- The radioactive metabolites of [3H] everolimus do not significantly cross the blood-brain barrier.
- A dose-dependent brain penetration of everolimus, which is consistent with the hypothesis of saturation of an efflux pump present in the brain capillary endothelial cells.

- The co-administration of the Pgp inhibitor, cyclosporine, enhances the exposure of everolimus in the brain cortex, which is consistent with the inhibition of Pgp at the blood-brain barrier.

There are no clinical data on the distribution of everolimus in the human brain. Non-clinical studies in rats demonstrated distribution into the brain following administration by both the intravenous and oral routes.

Biotransformation

Everolimus is a substrate of CYP3A4 and Pgp. Following oral administration, everolimus is the main circulating component in human blood. Six main metabolites of everolimus have been detected in human blood, including three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus. These metabolites were also identified in animal species used in toxicity studies, and showed approximately 100 times less activity than everolimus itself. Hence, everolimus is considered to contribute the majority of the overall pharmacological activity.

Elimination

Mean oral clearance CL/F of everolimus after 10 mg daily dose in patients with advanced solid tumours was 24.5 l/h. The mean elimination half-life of everolimus is approximately 30 hours.

No specific excretion studies have been undertaken in cancer patients; however, data are available from the studies in transplant patients. Following the administration of a single dose of radiolabelled everolimus in conjunction with ciclosporin, 80% of the radioactivity was recovered from the faeces, while 5% was excreted in the urine. The parent substance was not detected in urine or faeces.

Steady-state pharmacokinetics

After administration of everolimus in patients with advanced solid tumours, steady-state $AUC_{0-\tau}$ was dose-proportional over the range of 5 to 10 mg daily dose. Steady-state was achieved within two weeks. C_{max} is dose-proportional between 5 and 10 mg. t_{max} occurs at 1 to 2 hours post-dose. There was a significant correlation between $AUC_{0-\tau}$ and pre-dose trough concentration at steady-state.

Special populations

Hepatic impairment

The safety, tolerability and pharmacokinetics of Afinitor were evaluated in two single oral dose studies of Afinitor tablets in 8 and 34 adult subjects with impaired hepatic function relative to subjects with normal hepatic function.

In the first study, the average AUC of everolimus in 8 subjects with moderate hepatic impairment (Child-Pugh B) was twice that found in 8 subjects with normal hepatic function.

In the second study of 34 subjects with different impaired hepatic function compared to normal subjects, there was a 1.6-fold, 3.3-fold and 3.6-fold increase in exposure (i.e. AUC_{0-inf}) for subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, respectively.

Simulations of multiple dose pharmacokinetics support the dosing recommendations in subjects with hepatic impairment based on their Child-Pugh status.

Based on the results of the two studies, dose adjustment is recommended for patients with hepatic impairment (see sections 4.2 and 4.4).

Renal impairment

In a population pharmacokinetic analysis of 170 patients with advanced solid tumours, no significant influence of creatinine clearance (25-178 ml/min) was detected on CL/F of everolimus. Post-transplant renal impairment (creatinine clearance range 11-107 ml/min) did not affect the pharmacokinetics of everolimus in transplant patients.

Paediatric population

In patients with SEGA, everolimus C_{min} was approximately dose-proportional within the dose range from 1.35 mg/m² to 14.4 mg/m².

In patients with SEGA, the geometric mean C_{min} values normalised to mg/m² dose in patients aged <10 years and 10-18 years were lower by 54% and 40%, respectively, than those observed in adults (>18 years of age), suggesting that everolimus clearance was higher in younger patients. Limited data in TSC patients <3 years of age (n=13) indicate that BSA-normalised clearance is about two-fold higher in patients with low BSA (BSA of 0.556 m²) than in adults. Therefore it is assumed that steady-state could be reached earlier in TSC patients <3 years of age (see section 4.2 for dosing recommendations).

The pharmacokinetics of everolimus have not been studied in patients younger than 1 year of age. It is reported, however, that CYP3A4 activity is reduced at birth and increases during the first year of life, which could affect the clearance in this patient population.

A population pharmacokinetic analysis including 111 patients who ranged from 1.0 to 27.4 years (including 18 patients 1 to less than 3 years of age with BSA 0.42 m² to 0.74 m²) showed that BSA-normalised clearance is in general higher in younger patients.

Elderly patients

In a population pharmacokinetic evaluation in cancer patients, no significant influence of age (27-85 years) on oral clearance of everolimus was detected.

Ethnicity

Oral clearance (CL/F) is similar in Japanese and Caucasian cancer patients with similar liver functions. Based on analysis of population pharmacokinetics, oral clearance CL/F is on average 20% higher in black transplant patients.

5.3 Pre-clinical safety data

The preclinical safety profile of everolimus was assessed in mice, rats, minipigs, monkeys and rabbits. The major target organs were male and female reproductive systems (testicular tubular degeneration, reduced sperm content in epididymides and uterine atrophy) in several species; lungs (increased alveolar macrophages) in rats and mice; pancreas (degranulation and vacuolation of exocrine cells in monkeys and minipigs, respectively, and degeneration of islet cells in monkeys) and eyes (lenticular anterior suture line opacities) in rats only. Minor kidney changes were seen in the rat (exacerbation of age-related lipofuscin in tubular epithelium, increases in hydronephrosis) and mouse (exacerbation of background lesions). There was no indication of kidney toxicity in monkeys or minipigs.

Everolimus appeared to spontaneously exacerbate background diseases (chronic myocarditis in rats, coxsackie virus infection of plasma and heart in monkeys, coccidian infestation of the gastrointestinal tract in minipigs, skin lesions in mice and monkeys). These findings were generally observed at systemic exposure levels within the range of therapeutic exposure or above, with the exception of the findings in rats, which occurred below therapeutic exposure due to a high tissue distribution.

In a male fertility study in rats, testicular morphology was affected at 0.5 mg/kg and above, and sperm motility, sperm head count, and plasma testosterone levels were diminished at 5 mg/kg, which caused a reduction in male fertility. (There was evidence of reversibility.

In animal reproductive studies female fertility was not affected. However, oral doses of everolimus in female rats at ≥ 0.1 mg/kg (approximately 4% the AUC_{0-24h} in patients receiving the 10 mg daily dose) resulted in increases of pre-implantation loss.

Everolimus crossed the placenta and was toxic to the foetus. In rats, everolimus caused embryo/feto-toxicity at systemic exposure below the therapeutic level. This was manifested as mortality and reduced foetal weight. The incidence of skeletal variations and malformations (e.g. sternal cleft) was increased at 0.3 and 0.9 mg/kg. In rabbits, embryotoxicity was evident in an increase in late resorptions.

In juvenile rat toxicity studies, systemic toxicity included decreased body weight gain, food consumption, and delayed attainment of some developmental landmarks, with full or partial

recovery after cessation of dosing. With the possible exception of the rat-specific lens finding (where young animals appeared to be more susceptible), it appears that there is no significant difference in the sensitivity of juvenile animals to the adverse reactions of everolimus as compared to adult animals. Toxicity study with juvenile monkeys did not show any relevant toxicity.

Genotoxicity studies covering relevant genotoxicity endpoints showed no evidence of clastogenic or mutagenic activity. Administration of everolimus for up to 2 years did not indicate any oncogenic potential in mice and rats up to the highest doses, corresponding respectively to 3.9 and 0.2 times the estimated clinical exposure.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose anhydrous
Crospovidone
Hypromellose
Lactose monohydrate
Magnesium stearate
Butylated hydroxytoluene

6.2 Incompatibilities

Not applicable.

6.3 Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from light and moisture.

Keep out of the reach and sight of children.

6.4 Nature and contents of container

PA/AL/PVC with Aluminium foil Packs containing 30 tablets.

6.5 Instructions for use and handling

The extent of absorption of everolimus through topical exposure is not known. Therefore caregivers are advised to avoid contact with suspensions of Afinitor Tablets. Hands should be washed thoroughly before and after preparation of the suspension.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

6.6 Manufacturer:

Novartis Pharma Stein AG, Switzerland

For Novartis Pharma AG, Basel, Switzerland

6.7 License Holder:

Novartis Israel Ltd

36 Shacham St., Petach-Tikva.